CervoMed Inc. CRVO 深 滬
等待開盤 03-26 09:30:00 美东时间
3.9922
+0.072
+1.84%
華盛通- 最 高4.17
- 今 開3.95
- 成交量 1.61万股
- 最 低 3.907
- 昨 收 3.92
- 總市值 3693.87万
- 52周最高 13.13
- 市盈率 靜 --
- 換手率 0.17%
- 52周最低 3.58
- 委 比 -51.13%
- 總股本 925.27万
- 歷史最高 17437.50
- 量 比 0.27
- 振 幅 6.71%
- 歷史最低 1.80
- 每 手 1
- 風險率 1.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Chardan Capital Maintains Buy on CervoMed, Raises Price Target to $21
Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $15 to $21.
03-18 20:19
CervoMed Q4 EPS $(0.88) Misses $(0.63) Estimate, Sales $8.726M Beat $966.667K Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.63) by 40.13 percent. This is a 10 percent decrease over losses of $(0.80) per share from the same
03-17 19:43
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
CervoMed Inc. reported positive Phase 2b RewinD-LB data for its lead drug candidate neflamapimod in dementia with Lewy bodies (DLB) and secured FDA alignment for its planned Phase 3 trial design. The company anticipates multiple catalysts in 2026, including initiating a Phase 3 trial for DLB, reporting Phase 2a results in ischemic stroke recovery and primary progressive aphasia, and launching the EXPERTS-ALS trial in amyotrophic lateral sclerosis...
03-17 11:30
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
CervoMed Inc. announced that its drug candidate neflamapimod will be featured in presentations at AD/PD 2026 in Copenhagen, Denmark. The Phase 2b RewinD-LB trial demonstrated significant slowing of clinical progression in dementia with Lewy bodies (DLB) patients without Alzheimer's disease co-pathology. Secondary analyses support the patient selection and dosing regimen for the planned Phase 3 trial, aiming to enrich for DLB patients without AD c...
03-12 11:00
CervoMed to Participate in Upcoming Investor Conferences
CervoMed Inc. announced its participation in two investor conferences in March 2026: the Leerink Global Healthcare Conference on March 11 and the 38th Annual ROTH Conference on March 23, which includes a fireside chat. The company's lead drug candidate, neflamapimod, targeting age-related brain disorders, has completed a Phase 2b trial and plans to initiate a Phase 3 trial later this year. A webcast of the fireside chat will be available on the c...
03-05 12:30
CervoMed Completes Phase 1 Volunteer Trial To Evaluate Pharmacokinetics Of Drug Product Having Only New Stable Crystal Form Of Neflamapimod, Related Updates Regarding Its Planned Phase 3 Trial In Dementia With Lewy Bodies
CervoMed Inc. (CervoMed or the Company) (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that it has successfully completed a Phase 1 healthy
03-04 20:32
CervoMed selects 50mg TID neflamapimod dosing for planned Phase 3 DLB trial
CervoMed selects 50mg TID neflamapimod dosing for planned Phase 3 DLB trial CervoMed Inc. announced completion of a Phase 1 healthy volunteer study evaluating the pharmacokinetics of a drug product containing a new, stable crystal form of neflamapimod and selected a 50 mg three-times-daily dosing re
03-04 20:31
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
CervoMed announced successful completion of a Phase 1 study for neflamapimod, using a new, stable crystal form manufactured with an improved process. The pharmacokinetic profile of this form aligns with the therapeutically active drug from the Phase 2b trial. For the upcoming Phase 3 trial in dementia with Lewy bodies (DLB), the dose will be increased to 50mg three times daily to ensure therapeutic plasma concentrations. This adjustment addresses...
03-04 12:30
美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
